SAB Biotherapeutics (SABS) Other Non-Current Assets (2021)
SAB Biotherapeutics (SABS) posted Other Non-Current Assets of $13.1 million for Q4 2021.
SAB Biotherapeutics (SABS) Other Non-Current Assets (2021) Analysis & Trends
SAB Biotherapeutics' Other Non-Current Assets history runs 1 years deep, the most recent figure standing at $13.1 million for Q4 2021.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $13.1 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $13.1 million (changed N/A YoY) and the FY2021 annual result came in at $13.1 million, changed N/A from the prior year.
- Other Non-Current Assets was $13.1 million for Q4 2021 at SAB Biotherapeutics.
- Across five years, Other Non-Current Assets topped out at $13.1 million in Q4 2021 and bottomed at $13.1 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 13.10 Mn |